A head-to-head comparison of two commercially available multi-ingredient supplements — V14™ (40+ components including dihydronicotinamide mononucleotide, trans-resveratrol, pterostilbene, taurine, and bioflavonoids) and AG1® (70+ ingredients plus five probiotic strains) — found that V14™-exposed C. elegans maintained significantly greater movement speed and mobility over time compared to both AG1® and solvent controls. Transcriptomic profiling of V14™-treated worms revealed upregulation of pathways governing metabolic regulation and stress response — both canonically implicated in longevity signaling.
The practical implications deserve cautious framing. C. elegans, while a validated and efficient aging model, shares only partial genetic homology with humans, and worm motility is a proxy for healthspan rather than a direct cardiovascular or cognitive measure. Critically, this research originates from Magnitude Biosciences, which is commercially associated with V14™ — an undisclosed conflict that warrants independent replication. The transcriptomic data are intriguing but mechanism-level: knowing that stress-response pathways are modulated doesn't confirm which of the 40+ ingredients drives the effect, a classic confound in polypharmacy supplement research. AG1®'s probiotic strains may also behave differently in worm intestinal biology than in humans, making its relative underperformance here difficult to extrapolate. Overall, this is hypothesis-generating rather than confirmatory evidence — useful for prioritizing ingredients for controlled human trials, but insufficient to inform supplementation decisions today.
